burtlancast
Member
- Joined
- Jan 1, 2013
- Messages
- 3,263
Impressive.
But i can't get my hands on the entire article.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Click Here if you want to upgrade your account
If you were able to post but cannot do so now, send an email to admin at raypeatforum dot com and include your username and we will fix that right up for you.
Is this the notorius "suicide" plant!?Impressive.
But i can't get my hands on the entire article.
Is this the notorius "suicide" plant!?
Here’s a good one
Randomized Clinical Trial to Assess the Effectiveness of Breast Irradiation Following Lumpectomy and Axillary Disection for Node-Negative Breast Cancer
Background: Although the conservation management of breast cancer has become a routine method of treatment in most centers, there is still considerable controversy surrounding the ultimate minimum treatment required for node-negative breast cancer to achieve adequate local control.
Purpose: Our purpose was to assess the value of breast irradiation in reducing breast relapse following conservation surgery for node-negative breast cancer. We attempted to define low-risk groups of women for breast and distant site relapse (i.e., recurrence outside the breast) who might be spared breast irradiation or adjuvant systemic therapy.
Methods: Eight hundred thirty-seven patients were randomly assigned to receive radiation therapy or no radiation therapy following lumpectomy and axillary dissection for node-negative breast cancer.
Results: Breast irradiation reduced relapse in the breast from 25.7% in the controls to 5.5% in the irradiated patients. There was no difference in survival between the two groups (median follow-up, 43 months). A low-risk group (<5%chance of relapse in the breast without irradiation) could not be defined. Tumor size (>2 cm), age (<40 years), and poor nuclear grade were important predictors for breast relapse. Age (<50 years) and poor nuclear grade were important predictors for mortality. The presence of ductal carcinoma in situ did not predict breast relapse. Conclusions: Breast irradiation significantly reduces breast relapse, but it does not influence survival. Important predictors of breast relapse are age, tumour size, and nuclear grade predict survival. Implications: Further follow-up may define an acceptable low-risk gropu for breast relapse. Until then, we recommend that all patients receive breast irradiation. Systemic adjuvant theraphy should be considered for patients with poor nuclear gradetumors. [J Natl Cancer inst 84:683–689, 1992]
The amygdalin consists of one molecule of benzaldehyde, one molecule of hydrocyanide and two glucose molecules. The first two molecules are toxic compounds, but in combination with glucose molecules they have no toxic activity. The vitamin B17 molecule is cleaved by two enzymes: β-glucosidase and rodenase. β-glucosidase is present in all cells. The concentration of this enzyme is higher in malignant than in healthy cells. Unlike β-glucosidase, rodenase is present only in healthy cells. In contact with the β-glucosidase enzyme, the release of sugars and toxic benzaldehyde and hydrocyanide occurs, which together destroy carcinogenic cells. Since cancer cells use glucose for their growth and development and contain 18 times more sugar receptors than healthy, by intake of vitamin B17 they absorb not only glucose but also toxic molecules and thus die out. Since the malignant cells do not contain rodenase, they can not be defended. If it reaches a healthy cell, the amygdalin is broken down into non-toxic thiocyanates under the effect of rodenase, and this does not allow the release of toxic components. Practically, poisonous hydrocyanide and benzaldehyde are formed only at the site of cancer, in the tumor cell, while not damaging healthy cell.
It was tested and shown not to work A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. - PubMed - NCBI https://www.nejm.org/doi/full/10.1056/NEJM198201283060410
Back in 2015 a systematic review by Cochrane found: ''The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk–benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.'' Laetrile treatment for cancer. - PubMed - NCBI
It was tested and shown not to work A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. - PubMed - NCBI https://www.nejm.org/doi/full/10.1056/NEJM198201283060410
Back in 2015 a systematic review by Cochrane found: ''The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk–benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.'' Laetrile treatment for cancer. - PubMed - NCBI
Mice with aggressive cancers were injected with raw garlic extract and it completely cured their cancer in this study, while ingestion of raw garlic extract did not:
A novel therapeutic anticancer property of raw garlic extract via injection but not ingestion
Opinions?
This makes sense to me, very exciting. I know a naturopath who fled to ecuador that has been quietly putting high grade frankincense distillations in breast cancer patients via IV. He has told me his data is 90% cure rate since 2014.
Mice with aggressive cancers were injected with raw garlic extract and it completely cured their cancer in this study, while ingestion of raw garlic extract did not:
A novel therapeutic anticancer property of raw garlic extract via injection but not ingestion
Opinions?